EGFR and neoplasm: Genotyping of tumors based on testing of circulating tumor DNA (ctDNA) released from cancer cells into the plasma (that is, liquid biopsy) is a minimally invasive alternative to tissue biopsy that may be particularly advantageous for identifying patients with mCRC who may benefit from anti-EGFR therapy19–21.